Crystal Growth & Design · 2019 · 12 citations · 39 references
Natural SciencesBiochemistryChemistryGreen ChemistryLyophilizationSolidificationCrystal ChemistryCrystallization AnalysisCrystallization ProcessesDrug SolubilityNucleationSolubility EnhancementCrystal Size AnalysisCrystallizationCrystallization ConditionsCrystallization MechanismsHeterogeneous NucleationHomogeneous NucleationSalt CrystallizationSolubility
Papaverine HCl was successfully suspended by slurry reactive crystallization with the use of isopropyl alcohol (IPA) at 25 °C, a solid-to-liquid ratio of 0.19 g/mL, an aging time of 8 h, a yield of 82.0 w/w %, crystal sizes of 200–400 μm, and the value for enthalpy of fusion of 154.5 J/g. The poor solubility of papaverine in IPA and better solubility of papaverine HCl in water-containing IPA had made the homogeneous nucleation of papaverine HCl dominate. Crystal size and crystallinity of papaverine HCl were time and temperature dependent. However, the 1:1 haloperidol–maleic acid salt was also successfully suspended and generated by slurry reactive crystallization with the use of water at 25 °C, a solid-to-liquid ratio of 0.18 g/mL, an aging time of 8 h, a yield of 82.0 w/w %, crystal sizes of 500–1000 μm, and the value for enthalpy of fusion of 84.9 J/g. The poor solubility of haloperidol and 1:1 haloperidol–maleic acid salt in water had made the heterogeneous nucleation of 1:1 haloperidol–maleic acid salt dominate. Crystal size and crystallinity of 1:1 haloperidol–maleic acid salt became less sensitive to time and temperature. Comparing with grinding, solution reactive crystallization by cooling, and solution recrystallization by cooling, slurry reactive crystallization was a simple, robust, straightforward, low-constant-temperature, low-solvent-volume, and environmentally benign process giving comparable yield, particle size distribution, and crystallinity. Moreover, the use of a poor solvent in the slurry reactive crystallization enabled the recycling of the mother liquor without any significant loss in yield and crystallinity up to three cycles.
39
Pharmaceutical Crystallization
Jie Chen, Bipul Sarma, James M. B. Evans et al. · Crystal Growth & Design · 2011 · 563 citations